Claims
- 1. A method of treating a patient with atherosclerosis, said method comprising administering to said patient an inhibitor of SDF-1 or CXCR4 biological activity, said administering in an amount effective to reduce said symptoms of said atherosclerosis, said inhibitor being an inhibitor of T-cell or monocyte chemotaxis.
- 2. A method of treating a patient with a vascular disease, said method comprising administering to said patient an inhibitor of the interaction between stromal cell derived factor-1 (SDF-1) and platelets, in an amount effective to reduce the symptoms of said disease.
- 3. The method of claim 2, wherein said vascular disease is atherosclerosis.
- 4. The method of claim 3, wherein said inhibitor reduces the disruption of atherosclerotic plaques.
- 5. The method of claim 2, wherein said vascular disease is acute thrombosis.
- 6. The method of claim 2, wherein said inhibitor reduces the platelet-induced thrombus formation.
- 7. The method of claim 2, wherein said inhibitor reduces the occurrence of stroke, myocardial infarction, pulmonary embolism, or deep vein thrombosis.
- 8. The method of claim 2, wherein said inhibitor inhibits the interaction between SDF-1 and the platelet chemokine receptor, CXCR4.
- 9. The method of claim 8, wherein said inhibitor is an antibody to SDF-1, an antibody to CXCR4, or a CXCR4 inhibitor.
- 10. The method of claim 9, wherein said CXCR4 inhibitor is T22[Tyr5,12, Lys7]-polyphemusin II, ALX40-4C, or AMD3100.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of and claims priority from U.S. patent application Ser. No. 09/336,414, filed on Jun. 18, 1999, which in turn claims priority from U.S. provisional application 60/089,970, filed on Jun. 19, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60089970 |
Jun 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09336414 |
Jun 1999 |
US |
Child |
09804606 |
Mar 2001 |
US |